Fremont, Ca – October 27, 2015– Quark Pharmaceuticals, Inc, a late clinical-stage pharmaceutical company, who is a leader in the discovery and development of novel RNA interference (RNAi)-based therapeutics, announced today that it has initiated the U.S. arm of a global Phase II/III pivotal study (NCT02341560) of QPI-1007 for treatment of acute non arteritic anterior […]
The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at least one siRNA which down regulates expression of a target gene associated with loss […]
http://www.informa-ls.com/event/eurotides2015
The present invention relates to pharmaceutical compositions useful for topical, non-invasive delivery of an oligonucleotide to the ear and to methods for the treatment of an ear disorder, including hearing loss arising from chemical-induced ototoxicity, acoustic trauma and presbycusis; and microbial infections. The method comprises topically administering to the ear of a subject in need […]
The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein.
Read More…
The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences […]
The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient […]
Relationship Between Delayed Graft Function (DGF) Severity and Predicted DGF Risk
E. Squiers,1 B. Irish,1 D. Odenheimer,1 S. Erlich,1 J. Grinyo, S. Feng, On Behalf of Quark DGF Study Investigators.
1Quark, Fremont
2UCSF, SF
3U of Barcelona, BCN, Spain.
Meeting: 2015 American Transplant Congress
Abstract number: 448
Keywords: Cadaveric organs, Graft function, Kidney transplantation, Outcome
http://www.atcmeetingabstracts.com/abstract/relationship-between-delayed-graft-function-dgf-severity-and-predicted-dgf-risk/
Results of a Large Phase 2 siRNA Study: Target Expression Translates to Therapeutic Outcomes
Results of large (N=326) P2 study showed QPI-1002, a systemically administered siRNA targeting p53, significantly reduced the clinical endpoint of severity of delayed graft function post-transplant, especially in kidneys from older donors (p<0.016); which are known to have increased p53. A P3 […]
A Synthetic Chemically Modified siRNA Targeting Caspase 2 as a Therapeutic Agent for Ocular Neuroprotection
https://www.gtcbio.com/conferences/ocular-diseases-drug-discovery-speakers